Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults

Sisliyan C, Andres JT, Keyashian K. Effects of Age on Inflammatory Bowel Disease Presentation and Management in Older Adults. Dig Dis Sci. 2026 Aug 9.[...]

Staff Perspectives on Optimising Organisational Responses to Patient-Initiated Workplace Violence

Cannedy S, Lesser R, Yano EM, Hamilton AB, Fenwick KM. Staff Perspectives on Optimising Organisational Responses to Patient-Initiated Workplace Violence. J Adv Nurs. 2026 Aug[...]

Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration

Ghassemi S, Singh JA, Jiang R, Young-Xu Y, Cunningham FE, Glassman PA, Zhao X, Salone C, Au A, Miller DR, Her Q, Dong D, Aspinall[...]